HLA-G and neoplasm: Currently, to bring HLA-G blockade therapy into clinical reality, several problems have yet to be solved, such as identifying predictive biomarkers for assessing the therapeutic effectiveness and elucidating the exact ways in which environmental factors and/or genetic changes regulate the expression of HLA-G in tumor or immune cells.